These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1215 related articles for article (PubMed ID: 15664014)

  • 41. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
    Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
    J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
    Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH
    Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
    Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
    J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoclast differentiation and activation.
    Boyle WJ; Simonet WS; Lacey DL
    Nature; 2003 May; 423(6937):337-42. PubMed ID: 12748652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
    Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
    Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).
    Gao YH; Shinki T; Yuasa T; Kataoka-Enomoto H; Komori T; Suda T; Yamaguchi A
    Biochem Biophys Res Commun; 1998 Nov; 252(3):697-702. PubMed ID: 9837769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M; Amano S
    J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dental cells express factors that regulate bone resorption.
    Rani CS; MacDougall M
    Mol Cell Biol Res Commun; 2000 Mar; 3(3):145-52. PubMed ID: 10860862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
    J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
    Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS
    Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.